KRAS and Miyoshi myopathy: Mutations in potentially actionable genes were present in 49% of our cohort (KRAS, NRAS, BRAF, CCND1, EGFR), according to a recent publication that listed a number of 30 actionable MM genes.2 These mutations were most common within the MAPK pathway, additionally we identified a targetable p.Arg132Gly mutation in IDH1 one patient of our cohort.